Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings
- -- On-track to initiate IND-enabling activities for Wilson's Disease program in 4Q 2024, with IND or CTA filing expected in 1H 2026 -- CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the Company will highlight advances from across its Prime Editing pipeline and platform at the upcoming European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress, being held October 22-25, 2024 in Rome, and the American Association for the Study of Liver Diseases (AASLD), being held November 15-19, 2024 in San Diego.
- 10/15/2024
|
PRME Stock Rises 11.8% on Collaboration With Bristol Myers
- Prime Medicine collaborates with Bristol Myers Squibb for the development of T-cell therapies. Shares gain.
- 10/01/2024
|
Got $100? Consider Buying These 2 Penny Stocks in October
- You've likely heard that penny stocks are high-risk investments, and if so, you've heard right.
- 10/01/2024
|
Why Prime Medicine Stock Soared Nearly 12% Higher on Monday
- Changes are afoot at the company, and investors welcomed them.
- 09/30/2024
|
Crude Oil Moves Higher; Prime Medicine Shares Spike Higher
- U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 200 points during on Monday.
- 09/30/2024
|
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
- On Monday, Prime Medicine Inc. PRME announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co BMY to develop reagents for the next generation of ex vivo T-cell therapies.
- 09/30/2024
|
Prime Medicine Unveils Strategically Focused Pipeline
- -- Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime Medicine to Generate Follow-on Candidates Rapidly and Efficiently -- -- Initial Clinical Data from Phase 1/2 Trial in CGD Expected in 2025 While Advancing Wilson's Disease Program Toward Expected IND Application and/or CTA in 1H 2026 --
- 09/30/2024
|
2 Growth Stocks That Could Make You Richer
- Prime Medicine is pioneering prime-editing technology for genetic disorders, with the potential for long-term growth despite its early-stage status. Rocket Lab USA is capturing market share in the expanding commercial space industry with its small satellite launch services and vertical-integration strategy.
- 08/28/2024
|
Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings?
- While Prime Medicine's (PRME) pipeline progress is encouraging, the precarious cash position is worrisome. We advise a wait-and-watch approach before Q2 results.
- 07/31/2024
|
Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?
- While Prime Medicine (PRME) exhibits potential with its encouraging pipeline progress, the current cash position warrants caution. We advise a wait-and-watch approach at current levels.
- 07/19/2024
|
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
- We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX.
- 06/21/2024
|
Wall Street Analysts Believe Prime Medicine, Inc. (PRME) Could Rally 120.95%: Here's is How to Trade
- The average of price targets set by Wall Street analysts indicates a potential upside of 121% in Prime Medicine, Inc. (PRME). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 05/30/2024
|
If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names
- Biotech stocks are not for the faint of heart. It is a sector that can provide life-changing gains or cause an investment to head towards zero.
- 05/29/2024
|
Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio
- Alphabet manages more than $7 billion in equity investments, including a publicly traded portfolio. Its biggest holding competes with Microsoft's Github.
- 05/25/2024
|
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024
- The ARK Innovation ETF (NYSEARCA: ARKK ) has come under the spotlight recently, and there are three Cathie Wood stocks to buy with strong buy ratings for investors to consider in May this year. One of the key characteristics of the ARK Innovation ETF is its concentrated portfolio, typically holding between 35 to 55 stocks.
- 05/17/2024
|
Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024
- With innovation, millions of retiring baby boomers, demand for better care, patent cliffs, gene-editing, massive interest in weight-loss treatments, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead. Look at weight loss stocks, like Viking Therapeutics (NASDAQ: VKTX ), for example.
- 05/17/2024
|
Does Prime Medicine, Inc. (PRME) Have the Potential to Rally 133.64% as Wall Street Analysts Expect?
- The consensus price target hints at a 133.6% upside potential for Prime Medicine, Inc. (PRME). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 05/14/2024
|
Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
- CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Financial Officer of Prime Medicine, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024, at 4:30 p.m. ET in New York, NY.
- 05/13/2024
|
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
- -- Announced FDA clearance of first-ever IND application for a Prime Editing product, PM359, for the treatment of CGD; initial data from planned Phase 1/2 clinical trial expected in 2025 -- -- Presented new preclinical data demonstrating broad potential of Prime Editing technology at LNP Formulation and Process Development Summit and ASGCT 2024 --
- 05/10/2024
|
Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)
- Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Gran
- 05/08/2024
|
What Makes Prime Medicine, Inc. (PRME) a New Buy Stock
- Prime Medicine, Inc. (PRME) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 05/03/2024
|
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
- Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
- 04/29/2024
|
Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings
- -- Presentations include new preclinical data for PM359, further demonstrating ability of Prime Editors to efficiently, reproducibly and durably correct causative mutation of CGD; on track to enter clinical development in 2024, with initial data expected in 2025 -- -- Prime Medicine Co-Founder, David Liu, Ph.D., Awarded ASGCT Outstanding Achievement Award --
- 04/23/2024
|
2 Magnificent Growth Stocks With Room to Run
- Small-cap growth stocks could be on the brink of a major trend reversal. Prime Medicine and Tilray Brands, two small-cap stocks that appear significantly undervalued, could be smart buys ahead of a potential upswing in this group of stocks.
- 03/27/2024
|
Short-Squeeze Roulette: 3 Stocks That Could Leave Bears Begging
- A short squeeze is a financial phenomenon where rapidly increasing prices force short sellers to buy back stocks, pushing prices even higher. This situation often arises from a large number of investors betting against a stock, anticipating its decline.
- 03/14/2024
|
Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?
- The U.S. spends approximately $450 billion every year treating rare diseases. Investing guru Cathie Wood says managing patients afflicted with these illnesses could cost $20 trillion over their lifetime.
- 03/01/2024
|
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
- -- Maturing into clinical-stage company; on-track to file IND application or CTA for PM359 in 1H 2024, with initial data expected in 2025 -- -- Progressing broader portfolio across core areas of focus; expect to initiate IND-enabling activities in first liver and ocular disease programs in 2024 --
- 03/01/2024
|
Prime Medicine to Participate in Upcoming Investor Conferences
- CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in two upcoming conferences:
- 02/28/2024
|
Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
- CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten upsized public offering of 22,560,001 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 3,360,000 additional shares of its common stock, at a public offering price of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,200,005 shares of common stock at a public offering price of $6.24999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.00001 per share exercise price for each pre-funded warrant. All of the shares of common stock and pre-funded warrants in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $161.0 million.
- 02/20/2024
|
Prime Medicine Announces Pricing of Upsized Public Offering
- CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten upsized public offering of 19,200,001 shares of its common stock at a public offering price of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,200,005 shares of common stock at a public offering price of $6.24999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.00001 per share exercise price for each pre-funded warrant. Prime Medicine has also granted the underwriters a 30-day option to purchase up to an additional 3,360,000 shares of its common stock. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $140.0 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares and pre-funded warrants in the offering are to be sold by Prime Medicine. The offering is expected to close on or about February 20, 2024, subject to satisfaction of customary closing conditions.
- 02/14/2024
|
Prime Medicine Announces Proposed Public Offering of Common Stock
- CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock. Prime Medicine also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares of common stock in the proposed offering are to be sold by Prime Medicine. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- 02/14/2024
|
Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing
- Prime Medicine is a gene editing company at the forefront of genetic therapies, with a promising pipeline and preclinical successes. The company has made substantial investments in R&D, demonstrating its commitment to innovation and belief in its technology. Despite financial losses, Prime Medicine maintains a strong cash position, providing stability and flexibility for future growth.
- 01/28/2024
|
Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis
- CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the Cystic Fibrosis Foundation (CF Foundation) has agreed to provide the Company with up to $15 million to support the development of Prime Editors for the treatment of Cystic Fibrosis (CF).
- 01/25/2024
|
Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF
- BETHESDA, Md.--(BUSINESS WIRE)--Today, the Cystic Fibrosis Foundation announced that it will provide up to $15 million to Prime Medicine for preclinical research into gene editing for cystic fibrosis. Prime Medicine is using a gene editing technology called prime editing — a technology that enables insertions or deletions of small segments of DNA at precise sites. Prime Medicine — founded by researchers who pioneered the development of this unique editing technology — is investigating whether p.
- 01/25/2024
|
2 gene editing stocks to keep on your 2024 watchlist
- Gene therapy will get its share of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. NASDAQ: VRTX and CRISPR Therapeutics AG NASDAQ: CRSP CRISPR/Cas9-based treatment for sickle cell disease (SCD) in December 2023 kicked off the gene-editing revolution and mainstream attention.
- 01/23/2024
|
Wall Street Analysts Predict an 111.38% Upside in Prime Medicine, Inc. (PRME): Here's What You Should Know
- The mean of analysts' price targets for Prime Medicine, Inc. (PRME) points to an 111.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 01/09/2024
|
Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference
- CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 2:15 p.m. PT (5:15 p.m. ET) in San Francisco, CA.
- 01/02/2024
|
AI In Biotech: A Revolutionary Leap Forward Or Just Another Buzzword?
- AI isn't just revolutionizing biotech; it's reinventing it. From predicting diseases to accelerating drug discovery, AI is turning data into medical gold, reshaping how we approach healthcare innovation. AI is turbocharging techniques like CRISPR and Prime Editing, opening doors to previously unimaginable genetic breakthroughs. In the AI-enhanced biotech arena, traditional valuation metrics are old news. Speed, efficiency, and the ability to leapfrog development stages redefine how we value these trailblazing firms.
- 12/01/2023
|
1 Cathie Wood Stock That Could Deliver Life-Changing Returns in 10 Years
- Cathie Wood is known for investing in cutting-edge innovators. Her ARK Genomic Revolution ETF owns several gene-editing companies, but Prime Medicine might be the best of the bunch.
- 11/30/2023
|
Prime Medicine to Present at Upcoming Investor Conferences
- Cambridge, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today announced that company management will present at two upcoming investor conferences:
- 11/08/2023
|
7 Biotech Stocks to Get In Now Before Investors Catch On
- Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles happen with living organisms.
- 10/23/2023
|
Prime Medicine: Not Yet Primed For Retail Investment
- Prime Medicine is developing prime editing, a highly precise gene editing technology that offers advantages over traditional CRISPR-Cas9 gene editing. Prime editing has shown promising results in human cell lines, including correcting genetic causes of diseases. The company's lead program is focused on Chronic Granulomatous Disease (CGD), a rare genetic disorder that affects the immune system.
- 09/27/2023
|
2 Cathie Wood Stocks That Could Be Hidden Gems
- Cathie Wood has positions in several leading genomic medicine companies. Prime Medicine and Ginkgo Bioworks could be two of her fund's biggest winners in the years to come.
- 07/25/2023
|
Cathie Wood Goes Bargain-Hunting: 3 Stocks She Just Bought
- CrowdStrike, Prime Medicine, and Adaptive Biotechnologies were all on the Ark Invest shopping list on Thursday. CrowdStrike opened 8% lower on Thursday despite a "beat and raise" quarterly report.
- 06/02/2023
|
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
- UiPath, Prime Medicine, and Adaptive Biotechnologies were all on the Ark Invest shopping list on Thursday. Wood was particularly hungry for UiPath, adding shares of the robotics enterprise software specialist to all six of her funds.
- 05/26/2023
|
Prime Medicine to Present at Virtual Investor Conferences in May
- CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present at two virtual investor conferences in May:
- 05/17/2023
|
Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting
- Data demonstrated Prime Editors efficiently, reproducibly and durably corrected the causative mutation of CGD, supporting advancement of development candidate PM359
- 05/17/2023
|
Prime Medicine: Gene Editing Tech With Unique Approach
- Prime Medicine: Gene Editing Tech With Unique Approach.
- 04/23/2023
|
Prime Medicine to Present at Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days
- CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days on Monday, April 3, 2023 at 3:55 p.m. ET in New York, NY.
- 03/27/2023
|
Prime Medicine to Present at Cowen 43rd Annual Health Care Conference
- CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 9:50 a.m. ET in Boston, MA.
- 02/27/2023
|
Prime Medicine 'Crispr 3.0' Vs. Crispr Therapeutics
- CRISPR Therapeutics is probably the most widely-known company utilizing the original CRISPR-Cas9 gene editing method. Prime editing is a newer variation on CRISPR-Cas9 which is safer since it doesn't produce double-strand breaks in DNA.
- 01/12/2023
|
10 Potential 10x Return Stocks For The Next 10 Years
- While others flock to safety, should you do the opposite? Some of the best times to invest in highly speculative names are when no one wants them, as long as the reasons are macro and not company or industry specific.
- 01/04/2023
|
Prime Medicine to Present at 41st Annual J.P. Morgan Healthcare Conference
- CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 8:15 a.m. PT (11:15 a.m. ET) in San Francisco, CA.
- 01/03/2023
|
Prime Medicine: CRISPR 3.0 Company
- Prime Medicine's technology originated at Harvard/MIT and has been termed as CRISPR 3.0. Beam Therapeutics partnership in sickle cell disease and the experienced management add confidence in the Prime Editing technology.
- 10/24/2022
|
Gene-editing firm Prime Medicine slips in Nasdaq debut following big biotech IPO
- Prime Medicine Inc, a biotechnology company specializing in gene editing, debuted on the Nasdaq Thursday after pricing one of the year's largest IPOs in the sector. The Cambridge, Massachusetts-based company priced an upsized 10,294,118 shares of common stock at a public price of $17 each, good for expected gross proceeds of $175 million.
- 10/20/2022
|
Is Prime Medicine (PRME) Stock the Next Hot IPO?
- Prime Medicine (NASDAQ: PRME ) stock is catching the interest of traders on Thursday as the company launches its initial public offering (IPO) today! The company is launching an upsized offering that includes 10,294,118 shares of PRME stock priced at $17 each.
- 10/20/2022
|
Prime Medicine sets IPO terms, which could value the biotech at up to $1.7 billion
- Prime Medicine Inc. PRME, has set terms for its initial public offering, in which the Massachusetts-based biotechnology company, which utilizes gene-editing technology to develop therapies for a wide spectrum of diseases, looks to raise up $160.2 million. The company said it is offering 8.9 million shares in the IPO, which is expected to priced between $16 and $18 a share.
- 10/13/2022
|
